Income Statement Bio-Rad Laboratories, Inc.
Stocks
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
Pre-market 07:01:09 | |||
| 297.09 USD | +1.19% |
|
265.50 | -10.63% |
| 07-01 | Activist investors make bigger push for campaigns in H1, seek more M&A | RE |
| 06-03 | Bio-Rad Laboratories, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 08:45 AM |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B | |||||
Total Revenues | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B | |||||
Cost of Goods Sold, Total | 1.26B | 1.23B | 1.24B | 1.19B | 1.24B | |||||
Gross Profit | 1.67B | 1.57B | 1.43B | 1.38B | 1.34B | |||||
Selling General & Admin Expenses, Total | 853M | 825M | 824M | 814M | 820M | |||||
R&D Expenses | 258M | 257M | 241M | 296M | 258M | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 1.11B | 1.08B | 1.07B | 1.11B | 1.08B | |||||
Operating Income | 554M | 487M | 366M | 269M | 266M | |||||
Interest Expense, Total | -1.55M | -38.11M | -49.44M | -48.9M | -49M | |||||
Interest And Investment Income | 18.9M | 58M | 101M | 82M | 95.5M | |||||
Net Interest Expenses | 17.35M | 19.89M | 51.46M | 33.1M | 46.5M | |||||
Currency Exchange Gains (Loss) | -2.75M | 205K | 7.35M | 3.9M | 6.6M | |||||
Other Non Operating Income (Expenses) | 375K | -5.33M | 4.84M | 1.6M | -300K | |||||
EBT, Excl. Unusual Items | 569M | 502M | 429M | 308M | 319M | |||||
Restructuring Charges | -64.4M | -4.2M | -27.9M | - | -46.1M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 4.93B | -5.2B | -1.25B | -2.65B | 895M | |||||
Gain (Loss) On Sale Of Assets | - | 1.4M | - | - | - | |||||
Asset Writedown | - | - | - | - | -173M | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 5.44B | -4.7B | -850M | -2.34B | 996M | |||||
Income Tax Expense | 1.19B | -1.08B | -213M | -498M | 236M | |||||
Earnings From Continuing Operations | 4.25B | -3.63B | -637M | -1.84B | 760M | |||||
Net Income to Company | 4.25B | -3.63B | -637M | -1.84B | 760M | |||||
Net Income - (IS) | 4.25B | -3.63B | -637M | -1.84B | 760M | |||||
Net Income to Common Incl Extra Items | 4.25B | -3.63B | -637M | -1.84B | 760M | |||||
Net Income to Common Excl. Extra Items | 4.25B | -3.63B | -637M | -1.84B | 760M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 142.33 | -121.79 | -21.82 | -65.36 | 27.85 | |||||
Basic EPS - Continuing Operations | 142.33 | -121.79 | -21.82 | -65.36 | 27.85 | |||||
Basic Weighted Average Shares Outstanding | 29.83M | 29.78M | 29.21M | 28.21M | 27.28M | |||||
Net EPS - Diluted | 140.56 | -121.79 | -21.82 | -65.36 | 27.85 | |||||
Diluted EPS - Continuing Operations | 140.56 | -121.79 | -21.82 | -65.36 | 27.85 | |||||
Diluted Weighted Average Shares Outstanding | 30.21M | 29.78M | 29.21M | 28.21M | 27.28M | |||||
Normalized Basic EPS | 11.92 | 10.53 | 9.19 | 6.81 | 7.31 | |||||
Normalized Diluted EPS | 11.77 | 10.53 | 9.19 | 6.81 | 7.31 | |||||
Supplemental Items | ||||||||||
EBITDA | 688M | 624M | 512M | 421M | 432M | |||||
EBITA | 583M | 512M | 389M | 290M | 290M | |||||
EBIT | 554M | 487M | 366M | 269M | 266M | |||||
EBITDAR | 738M | 679M | 575M | 490M | 498M | |||||
Effective Tax Rate - (Ratio) | 21.92 | 22.89 | 25.03 | 21.27 | 23.67 | |||||
Current Domestic Taxes | 81.6M | 133M | 85.8M | 95M | 45.3M | |||||
Current Foreign Taxes | 32.6M | 24.1M | 17.4M | 28.5M | 17.7M | |||||
Total Current Taxes | 114M | 157M | 103M | 124M | 63M | |||||
Deferred Domestic Taxes | 1.05B | -1.2B | -307M | -606M | 193M | |||||
Deferred Foreign Taxes | 32.1M | -36.7M | -15.2M | -20.5M | -22.3M | |||||
Total Deferred Taxes | 1.08B | -1.24B | -323M | -627M | 170M | |||||
Normalized Net Income | 356M | 314M | 268M | 192M | 199M | |||||
Interest on Long-Term Debt | 800K | 800K | 700K | 700K | 700K | |||||
Non-Cash Pension Expense | 600K | -400K | 2M | 2.8M | 1.8M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 275M | 257M | 247M | 296M | 276M | |||||
Net Rental Expense, Total | 50.2M | 54.5M | 63.4M | 69.5M | 66.9M | |||||
Imputed Operating Lease Interest Expense | 2.77M | 20.62M | 17.95M | 19.56M | 19.01M | |||||
Imputed Operating Lease Depreciation | 47.43M | 33.88M | 45.45M | 49.94M | 47.89M | |||||
Stock-Based Comp., COGS (Total) | 4.9M | 5.4M | 6.1M | 6.5M | 6.3M | |||||
Stock-Based Comp., R&D Exp. (Total) | 8.3M | 9.9M | 11.3M | 12.9M | 11.4M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 38M | 45.6M | 43.9M | 42.9M | 40.3M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 51.2M | 60.9M | 61.3M | 62.3M | 58M |
- Stock Market
- Stocks
- BIO Stock
- Financials Bio-Rad Laboratories, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















